|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The author summarizes a brief analysis of associated cardiovascular disease and nutritional consequences, exploring the controversial cause-effect on mortality and technique failure.Therapeutic modalities aiming to reduce PPL (angiotensin-converting enzyme inhibitors [ACEI]s and vitamin D therapies) were explored, although it is unclear whether PPL represents a valid therapeutic target or, on the other hand, is solely a manifestation of endothelial dysfunction.
|
31088933 |
2020 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The aim of present study was to check the association of <i>ACE</i> I/D polymorphism with risk of diabetes in subjects with CVD.
|
30641607 |
2020 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Therapies targeting these RAS components, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, are commonly used for treatment of hypertension and cardiovascular diseases, with blood pressure-lowering effects attributed in part to sympathetic inhibition and parasympathetic facilitation.
|
30413906 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Abbreviations</b>: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CMI); Cardiovascular diseases (CVD); Diastolic blood pressure (DBP); Enzyme-linked immunosorbent assay (ELISA); Hematoxylin-eosin (H&E); Kidney mass index (KMI); Liver mass index (LMI); Mean arterial blood pressure (MAP); Plasma renin concentration (PRC); Renin-angiotensin system (RAS); Rennin (REN); Systolic blood pressure (SBP); Student-Newman-Keuls q test (SNK-q test); Spontaneous hypertension rats (SHR); Valsartan asleep Administration (VSA); Valsartan awake Administration (VWA); Wistar-Kyoto (WKY); Mesor (M); Amplitude (A); Phase (φ).
|
31096810 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
We observed a monotonically increasing association between quartiles of 2,5-DCP and prevalence of CVD.
|
30377258 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibitors of ACE are first line therapeutics used in the treatment of hypertension and related cardiovascular diseases.
|
31084594 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
There is evidence of beneficial effects of angiotensin converting enzyme (ACE) inhibitors on aspects related to frailty, such as physical function, even in those without cardiovascular disease.
|
30256910 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Use of protective angiotensin-converting enzyme inhibitors (ACE-I) in patients with cardiovascular disease (CVD) is sometimes limited by incident coughing.
|
29330882 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT<sub>1</sub>R) blockers, current therapies for hypertension and related cardiovascular diseases are still inadequate.
|
31537750 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Since more than three decades suppression of AngII generation by inhibition of the angiotensin-converting enzyme (ACE) or blockade of the AngII-receptor has shown clinical benefit by reducing hypertension, atherosclerosis and other inflammation-associated cardiovascular diseases.
|
29244531 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin converting enzyme (ACE) inhibitors are extensively used for the prevention and treatment of cardiovascular diseases with a wide range of clinical recommendations.
|
29468656 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The most common reasons for sub-optimal medication management were exposure to medications associated with falls, underuse of angiotensin-converting enzyme inhibitor/angiotensin-2 receptor blocker medications for cardiovascular disease and low rates of hemoglobin A1c and renal monitoring in patients with diabetes.
|
29917143 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
<b>Methods:</b> We reviewed the published pharmacokinetic (PK) and pharmacodynamic (PD) clinical data that report potential -or absence of- drug interactions between second-generation agents (SGAs) and CVD drugs most commonly used in cardiology, including antiplatelet drugs and anticoagulants, statins, beta-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, diuretics and the antiarrhythmic drugs amiodarone and digoxin.
|
30707042 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Alterations in ACE expression or activity are associated with various pathological phenotypes, particularly cardiovascular diseases.
|
31042763 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin converting enzyme (ACE) inhibitors have shown beneficial effects on endothelial function in patients with hypertension and other cardiovascular diseases, however there are few studies evaluating the effect of treatment with this class on the reduction of C-reactive protein (CRP) levels.
|
31337127 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Therefore, ACE is a key drug target for the treatment of cardiovascular system diseases.
|
30998765 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Compared with men with T2DM, women with T2DM were more likely to be obese, hypertensive, and have hypercholesterolemia, but were less likely to be prescribed lipid-lowering medication and angiotensin-converting enzyme inhibitors, especially if they had cardiovascular disease.
|
30986362 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Angiotensin-converting enzyme (ACE) inhibitors are the most frequently used class of drugs in the treatment of cardiovascular diseases.
|
30805791 |
2019 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Flavonoids diminish the risk of cardiovascular diseases and the flavonoid taxifolin normalizes the activity of ACE.
|
30148999 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Angiotensin-converting enzyme inhibitors (ACE-I) display vasoprotective activity and represent the cornerstone in the treatment of cardiovascular diseases.
|
28700133 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Initiation of CVD interventions [lipid-lowering drugs (LLDs), angiotensin-converting enzyme inhibitors (ACEIs), anti-hypertensives, invasive cardiovascular procedures (ICPs) were investigated and Poisson regression models calculated whether rates were lower among women than men, adjusting for potential confounders.
|
29509305 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
171 Indigenous people aged ≥20 years of age who had at least one clinical diagnosis of a CVD event, or in Canada and Australia had a 5-year CVD risk ≥15%, and were prescribed at least two of the following CVD medication classes: statin, aspirin, ACE inhibitors and beta blockers.
|
29371275 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Pharmacological therapy is very effective in lowering BP and in preventing CVD outcomes in most patients; first-line antihypertensive medications include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, dihydropyridine calcium-channel blockers and thiazide diuretics.
|
29565029 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
For those patients at risk of anaphylaxis who lack cardiovascular disease, it is recommended to avoid beta-blockers and possibly ACE inhibitors.
|
28552379 |
2018 |
|
Cardiovascular Diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Although traditional renin-angiotensin system antagonists including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have revolutionized the treatment of cardiovascular disease (CVD), the pivotal PARADIGM-HF trial demonstrated that sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), was superior to an angiotensin-converting enzyme inhibitor in reducing cardiovascular morbidity and mortality in patients with heart failure and reduced ejection fraction.
|
29464817 |
2018 |